All lobbying filings

INCYTE CORPORATION

Lobbying for INCYTE CORPORATION

Filing 2nd Quarter - Report

2nd Quarter (Apr 1 - June 30) 2026 · Delaware · House · Senate · $750,000.00 expenses · posted Jul 20, 2026

Official filing document

Bills named in this filing 4

HR 946
ORPHAN Cures Act
S 1862
ORPHAN Cures Act
HRES 1331
Expressing support for the designation of June 1, 2026, through June 7, 2026, as "Hidradenitis Suppurativa Awareness We…
S 2658
Medication Affordability and Patent Integrity Act

Lobbying activity 1

Medicare/Medicaid

H.R. 946 / S. 1862, Orphan Cures Act implementation H. Res. 1331, Expressing support for "Hidradenitis Suppurativa Awareness Week" S. 2658, Medication Affordability and Patent Integrity Act Issues related to Medicaid rebates Issues related to implementation of the Inflation Reduction Act Issues related to the 340B Drug Pricing Program Issues related to drug cost and pricing Education around access to innovative therapies in dermatology

Source: federal Lobbying Disclosure Act filing. Bills are parsed from the activity descriptions.